Aspect Partners LLC Boosts Stock Position in Amgen Inc. $AMGN

Aspect Partners LLC raised its position in shares of Amgen Inc. (NASDAQ:AMGN) by 70.8% in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 987 shares of the medical research company’s stock after buying an additional 409 shares during the quarter. Aspect Partners LLC’s holdings in Amgen were worth $276,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Nuveen LLC acquired a new stake in Amgen in the first quarter valued at approximately $688,868,000. Federated Hermes Inc. grew its stake in Amgen by 48.5% during the 1st quarter. Federated Hermes Inc. now owns 2,037,169 shares of the medical research company’s stock worth $634,680,000 after buying an additional 665,555 shares during the last quarter. The Manufacturers Life Insurance Company grew its stake in Amgen by 128.9% during the 1st quarter. The Manufacturers Life Insurance Company now owns 1,065,694 shares of the medical research company’s stock worth $332,017,000 after buying an additional 600,096 shares during the last quarter. WoodTrust Financial Corp increased its position in Amgen by 8,223.6% during the 2nd quarter. WoodTrust Financial Corp now owns 595,634 shares of the medical research company’s stock valued at $166,307,000 after buying an additional 588,478 shares in the last quarter. Finally, Kingstone Capital Partners Texas LLC purchased a new stake in Amgen in the second quarter valued at about $156,812,000. 76.50% of the stock is currently owned by institutional investors.

Amgen Stock Performance

Shares of NASDAQ AMGN opened at $315.59 on Friday. The company has a market capitalization of $169.90 billion, a PE ratio of 25.80, a price-to-earnings-growth ratio of 2.61 and a beta of 0.45. The company has a debt-to-equity ratio of 7.24, a quick ratio of 0.98 and a current ratio of 1.31. The company’s fifty day moving average price is $289.29 and its 200 day moving average price is $288.18. Amgen Inc. has a 1 year low of $253.30 and a 1 year high of $335.88.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Tuesday, November 4th. The medical research company reported $5.64 earnings per share for the quarter, beating the consensus estimate of $5.01 by $0.63. The firm had revenue of $9.56 billion during the quarter, compared to analyst estimates of $8.98 billion. Amgen had a return on equity of 174.71% and a net margin of 18.96%.Amgen’s revenue for the quarter was up 12.4% compared to the same quarter last year. During the same quarter in the previous year, the business earned $5.58 EPS. Amgen has set its FY 2025 guidance at 20.600-21.400 EPS. On average, research analysts predict that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, December 12th. Stockholders of record on Friday, November 21st will be paid a dividend of $2.38 per share. This represents a $9.52 annualized dividend and a dividend yield of 3.0%. The ex-dividend date of this dividend is Friday, November 21st. Amgen’s dividend payout ratio is presently 73.57%.

Analyst Upgrades and Downgrades

AMGN has been the topic of a number of research analyst reports. The Goldman Sachs Group dropped their price target on Amgen from $405.00 to $400.00 and set a “buy” rating on the stock in a research note on Wednesday. Piper Sandler reiterated an “overweight” rating on shares of Amgen in a research note on Wednesday. Wells Fargo & Company upped their price target on shares of Amgen from $280.00 to $300.00 and gave the company an “overweight” rating in a research note on Wednesday. Cantor Fitzgerald raised their price target on shares of Amgen from $305.00 to $315.00 and gave the stock a “neutral” rating in a report on Thursday. Finally, Wall Street Zen lowered shares of Amgen from a “buy” rating to a “hold” rating in a report on Monday, October 27th. Eight analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $307.89.

Insider Activity

In related news, SVP Nancy A. Grygiel sold 1,267 shares of Amgen stock in a transaction on Wednesday, August 20th. The shares were sold at an average price of $296.99, for a total value of $376,286.33. Following the sale, the senior vice president owned 7,209 shares of the company’s stock, valued at approximately $2,141,000.91. This trade represents a 14.95% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.76% of the stock is owned by company insiders.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.